본문 바로가기
KERD
논문KCI 등재

Prevention and Management of Cerebral Small Vessel Disease

Jong S. Kim|Vincent Mok
대한뇌졸중학회 (The Korean Stroke Society)|2015.05|대한뇌졸중영문학회지 (Journal of stroke)|제17권 제2호|pp. 111-122

2

조회

0

다운로드

3

인용

0

참고문헌

키워드

PreventionTreatmentSmall vessel disease
주제분류신경과학

초록

Lacunar infarcts/lacunes, white matter hyperintensities (WMH), and cerebral microbleeds (CMBs) are considered various manifestations of cerebral small vessel disease (SVD). Since the exact mechanisms of these manifestations differ, their associated risk factors differ. High blood pressure is the most consistent risk factor for all of these manifestations. However, a “J curve” phenomenon in terms of blood pressure probably exists for WMH. The association between cholesterol levels and lacunar infarcts/lacunes or WMH was less consistent and sometimes conflicting; a low cholesterol level probably increases the risk of CMBs. Homocysteinemia appears to be associated with WMH. It is noteworthy that the risk factors profile may also differ between different lacunar patterns and CMBs located at different parts of the brain. Thrombolysis, antihypertensives, and statins are used to treat patients with symptomatic lacunar infarction, just as in those with other stroke subtypes. However, it should be remembered that bleeding risks increase in patients with extensive WMH and CMBs after thrombolysis therapy. According to the Secondary Prevention of Small Subcortical Strokes trial results, a blood pressure reduction to <130 mmHg is recommended in patients with symptomatic lacunar infarction. However, an excessive blood pressure decrease may induce cognitive decline in older patients with extensive WMH. Dual antiplatelet therapy (aspirin plus clopidogrel) should be avoided because of the excessive risk of intracerebral hemorrhage. Although no particular antiplatelet is recommended, drugs such as cilostazol or triflusal may have advantages for patients with SVD since they are associated with less frequent bleeding complications than aspirin

Abstract

Lacunar infarcts/lacunes, white matter hyperintensities (WMH), and cerebral microbleeds (CMBs) are considered various manifestations of cerebral small vessel disease (SVD). Since the exact mechanisms of these manifestations differ, their associated risk factors differ. High blood pressure is the most consistent risk factor for all of these manifestations. However, a “J curve” phenomenon in terms of blood pressure probably exists for WMH. The association between cholesterol levels and lacunar infarcts/lacunes or WMH was less consistent and sometimes conflicting; a low cholesterol level probably increases the risk of CMBs. Homocysteinemia appears to be associated with WMH. It is noteworthy that the risk factors profile may also differ between different lacunar patterns and CMBs located at different parts of the brain. Thrombolysis, antihypertensives, and statins are used to treat patients with symptomatic lacunar infarction, just as in those with other stroke subtypes. However, it should be remembered that bleeding risks increase in patients with extensive WMH and CMBs after thrombolysis therapy. According to the Secondary Prevention of Small Subcortical Strokes trial results, a blood pressure reduction to <130 mmHg is recommended in patients with symptomatic lacunar infarction. However, an excessive blood pressure decrease may induce cognitive decline in older patients with extensive WMH. Dual antiplatelet therapy (aspirin plus clopidogrel) should be avoided because of the excessive risk of intracerebral hemorrhage. Although no particular antiplatelet is recommended, drugs such as cilostazol or triflusal may have advantages for patients with SVD since they are associated with less frequent bleeding complications than aspirin

참고문헌 (104)

  1. Debette S, "The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: Systematic review and meta-analysis", BMJ, 341, pp.c3666~ (2010)
  2. Altmann-Schneider I, "Cerebral microbleeds are predictive of mortality in the elderly", Stroke, 42, pp.638~644 (2011)
  3. Wardlaw JM, "Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration", Lancet Neurol, 12, pp.822~838 (2013)
  4. Khan U, "Risk factor profile of cerebral small vessel disease and its subtypes", J Neurol Neurosurg Psychiatry, 78, pp.702~706 (2007)
  5. Boiten J, "Two clinically distinct lacunar infarct entities? A hypothesis", Stroke, 24, pp.652~656 (1993)
  6. Arauz A, "Prospective study of single and multiple lacunar infarcts using magnetic resonance imaging: risk factors, recurrence, and outcome in 175 consecutive cases", Stroke, 34, pp.2453~2458 (2003)
  7. Nah HW, "Diversity of single small subcortical infarctions according to infarct location and parent artery disease: analysis of indicators for small vessel disease and atherosclerosis", Stroke, 41, pp.2822~2827 (2010)
  8. Longstreth WT, Jr, "Lacunar infarcts defined by magnetic resonance imaging of 3660 elderly people: the cardiovascular health study", Arch Neurol, 55, pp.1217~1225 (1998)
  9. Bezerra DC, "Risk factors for lacune subtypes in the atherosclerosis risk in communities (aric) study", Neurology, 78, pp.102~108 (2012)
  10. van Dijk EJ, Prins, "Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: Rotterdam Scan study", Stroke, 39, pp.2712~2719 (2008)
  11. Gouw AA, "Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability Study", Stroke, 39, pp.1414~1420 (2008)
  12. McQuinn BA, "White matter lucencies on computed tomography, subacute arteriosclerotic encephalopathy (binswanger’s disease), and blood pressure", Stroke, 18, pp.900~905 (1987)
  13. Sulkava R, "Vascular dementia due to cardiac arrhythmias and systemic hypotension", Acta Neurologica Scandinavica, 76, pp.123~128 (1987)
  14. Pantoni L, "Cerebrospinal fluid proteins in patients with leucoaraiosis: possible abnormalities in blood-brain barrier function", J Neurol Sci, 115, pp.125~131 (1993)
  15. Moody DM, "Periventricular venous collagenosis: association with leukoaraiosis", Radiology, 194, pp.469~476 (1995)
  16. Conklin J, "Are acute infarcts the cause of leukoaraiosis? Brain mapping for 16 consecutive weeks", Ann Neurol, 76, pp.899~904 (2014)
  17. Liao D, "The prevalence and severity of white matter lesions, their relationship with age, ethnicity, gender, and cardiovascular disease risk factors: the ARIC study", Neuroepidemiology, 16, pp.149~162 (1997)
  18. Longstreth WT Jr, "Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study", Stroke, 27, pp.1274~1282 (1996)
  19. Jeerakathil T, "Stroke risk profile predicts white matter hyperintensity volume : the Framingham Study", Stroke, 35, pp.1857~1861 (2004)
  20. de Leeuw FE, "Hypertension and cerebral white matter lesions in a prospective cohort study", Brain, 125, pp.765~772 (2002)
  21. Dufouil C, "Longitudinal study of blood pressure and white matter hyperintensities: the EVA MRI cohort", Neurology, 56, pp.921~926 (2001)
  22. van Dijk EJ, "The association between blood pressure, hypertension, and cerebral white matter lesions: cardiovascular determinants of dementia study", Hypertension, 44, pp.625~630 (2004)
  23. Bakker SL, "Cerebral vasomotor reactivity and cerebral white matter lesions in the elderly", Neurology, 52, pp.578~583 (1999)
  24. Mok V, "Predictors for cognitive decline in patients with confluent white matter hyperintensities", Alzheimers Dement, 8(Suppl), pp.S96~S103 (2012)
  25. Brickman AM, "Long-term blood pressure fluctuation and cerebrovascular disease in an elderly cohort", Arch Neurol, 67, pp.564~569 (2010)
  26. Goldstein IB, "Relationship between blood pressure and subcortical lesions in healthy elderly people", Stroke, 29, pp.765~772 (1998)
  27. Ylikoski A, "White matter hyperintensities on mri in the neurologically nondiseased elderly. Analysis of cohorts of consecutive subjects aged 55 to 85 years living at home", Stroke, 26, pp.1171~1177 (1995)
  28. Vermeer SE, "Homocysteine, silent brain infarcts, and white matter lesions: The Rotterdam Scan study", Ann Neurol, 51, pp.285~289 (2002)
  29. Hassan A, "Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction", Brain, 127, pp.212~219 (2004)
  30. de Lau LM, "Plasma vitamin B12 status and cerebral white-matter lesions", J Neurol Neurosurg Psychiatry, 80, pp.149~157 (2009)
  31. de Lau LM, "Plasma folate concentration and cognitive performance: Rotterdam scan study", Am J Clin Nutrition, 86, pp.728~734 (2007)
  32. Longstreth WT Jr, "Plasma total homocysteine levels and cranial magnetic resonance imaging findings in elderly persons: the cardiovascular health study", Arch Neurol, 61, pp.67~72 (2004)
  33. Vuorinen M, "Changes in vascular risk factors from midlife to late life and white matter lesions: a 20-year follow-up study", Dementia Geriatr Cog Disorders, 31, pp.119~125 (2011)
  34. Carmelli D, "Midlife cardiovascular risk factors and brain morphology in identical older male twins", Neurology, 52, pp.1119~1124 (1999)
  35. Schmidt R, "Magnetic resonance imaging white matter hyperintensities in clinically normal elderly individuals. Correlations with plasma concentrations of naturally occurring antioxidants", Stroke, 27, pp.2043~2047 (1996)
  36. Jimenez-Conde J, "Hyperlipidemia and reduced white matter hyperintensity volume in patients with ischemic stroke", Stroke, 41, pp.437~442 (2010)
  37. Xu H, "Distinctive RNA expression profiles in blood associated with white matter hyperintensities in brain", Stroke, 41, pp.2744~2749 (2010)
  38. Simpson JE, "Microarray rna expression analysis of cerebral white matter lesions reveals changes in multiple functional pathways", Stroke, 40, pp.369~375 (2009)
  39. Fornage M, "Genome-wide association studies of cerebral white matter lesion burden: the charge consortium", Ann Neurology, 69, pp.928~939 (2011)
  40. Schmidt R, "Progression of cerebral white matter lesions: 6-year results of the Austrian Stroke Prevention Study", Lancet, 361, pp.2046~2048 (2003)
  41. Markus HS, "Markers of endothelial and hemostatic activation and progression of cerebral white matter hyperintensities: Longitudinal results of the Austrian Stroke Prevention Study", Stroke, 36, pp.1410~1414 (2005)
  42. Longstreth WT Jr, "Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: The Cardiovascular Health Study", Stroke, 36, pp.56~61 (2005)
  43. Godin O, "Antihypertensive treatment and change in blood pressure are associated with the progression of white matter lesion volumes: The three-city (3c)-dijon magnetic resonance imaging study", Circulation, 123, pp.266~273 (2011)
  44. Gottesman RF, "Blood pressure and white-matter disease progression in a biethnic cohort: atherosclerosis Risk In Communities (ARIC) study", Stroke, 41, pp.3~8 (2010)
  45. Xiong Y, "Prestroke statins, progression of white matter hyperintensities, and cognitive decline in stroke patients with confluent white matter hyperintensities", Neurotherapeutics, 11, pp.606~611 (2014)
  46. van Dijk EJ, "C-reactive protein and cerebral small-vessel disease : the Rotterdam Scan study", Circulation, 112, pp.900~905 (2005)
  47. Schmidt R, "C-reactive protein, carotid atherosclerosis, and cerebral small-vessel disease: results of the Austrian Stroke Prevention Study", Stroke, 37, pp.2910~2916 (2006)
  48. Wang Z, "Cerebral microbleeds: is antithrombotic therapy safe to administer?", Stroke, 45, pp.2811~2817 (2014)
  49. Cordonnier C, "Spontaneous brain microbleeds: systematic review, subgroup analyses and standards for study design and reporting", Brain, 130, pp.1988~2003 (2007)
  50. Poels MM, "Prevalence and risk factors of cerebral microbleeds: an update of the Rotterdam Scan study", Stroke, 41, pp.S103~106 (2010)
  51. Staals J, "Brain microbleeds relate to higher ambulatory blood pressure levels in first-ever lacunar stroke patients", Stroke, 40, pp.3264~3268 (2009)
  52. Park JH, "Differential risk factors for lacunar stroke depending on the mri (white and red) subtypes of microangiopathy", PLoS One, 7, pp.e44865~ (2012)
  53. Lee SH, "Low concentration of serum total cholesterol is associated with multifocal signal loss lesions on gradient-echo magnetic resonance imaging: analysis of risk factors for multifocal signal loss lesions", Stroke, 33, pp.2845~2849 (2002)
  54. Wieberdink RG, "Serum lipid levels and the risk of intracerebral hemorrhage: the Rotterdam study", Arterioscler Thromb Vasc Biology, 31, pp.2982~2989 (2011)
  55. Haussen DC, "Statin use and microbleeds in patients with spontaneous intracerebral hemorrhage", Stroke, 43, pp.2677~2681 (2012)
  56. Day JS, "Previous statin use is not associated with an increased prevalence or degree of gradient-echo lesions in patients with acute ischemic stroke or transient ischemic attack", Stroke, 42, pp.354~358 (2011)
  57. Ovbiagele B, "Strong independent correlation of proteinuria with cerebral microbleeds in patients with stroke and transient ischemic attack", Arch Neurol, 67, pp.45~50 (2010)
  58. Maxwell SS, "Genetic associations with brain microbleeds: systematic review and meta-analyses", Neurology, 77, pp.158~167 (2011)
  59. Gregoire SM, "MRI detection of new microbleeds in patients with ischemic stroke: five-year cohort follow-up study", Stroke, 41, pp.184~186 (2010)
  60. Poels MM, "Incidence of cerebral microbleeds in the general population: the Rotterdam Scan study", Stroke, 42, pp.656~661 (2011)
  61. Goos JD, "Incidence of cerebral microbleeds : a longitudinal study in a memory clinic population", Neurology, 74, pp.1954~1960 (2010)
  62. "The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study group. Tissue plasminogen activator for acute ischemic stroke", N Engl J Med, 333, pp.1581~1587 (1995)
  63. Hsia AW, "Efficacy of IV tissue plasminogen activator in acute stroke: does stroke subtype really matter?", Neurology, 61, pp.71~75 (2003)
  64. Fluri F, "Intravenous thrombolysis in patients with stroke attributable to small artery occlusion", Eur J Neurol, 17, pp.1054~1060 (2010)
  65. Mustanoja S, "Outcome by stroke etiology in patients receiving thrombolytic treatment: Descriptive subtype analysis", Stroke, 42, pp.102~106 (2011)
  66. Fuentes B, "Efficacy of intravenous thrombolysis according to stroke subtypes: the Madrid Stroke Network Data", Eur J Neurol, 19, pp.1568~1574 (2012)
  67. Shobha N, "Do lacunar strokes benefit from thrombolysis? Evidence from the registry of the Canadian Stroke Network", Int J Stroke, 8(Suppl), pp.45~49 (2013)
  68. Jauch EC, "Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association", American Stroke Association, 2013, pp.44, 870~947
  69. Pantoni L, "Thrombolysis in acute stroke patients with cerebral small vessel disease", Cerebrovasc Dis, 37, pp.5~13 (2014)
  70. Neumann-Haefelin T, "Leukoaraiosis is a risk factor for symptomatic intracerebral hemorrhage after thrombolysis for acute stroke", Stroke, 37, pp.2463~2466 (2006)
  71. Palumbo V, "Leukoaraiosis and intracerebral hemorrhage after thrombolysis in acute stroke", Neurology, 68, pp.1020~1024 (2007)
  72. Demchuk AM, "Importance of leukoaraiosis on ct for tissue plasminogen activator decision making: evaluation of the NINDS rt-PA Stroke Study", Cerebrovasc Dis, 26, pp.120~125 (2008)
  73. Aries MJ, "Tpa treatment for acute ischaemic stroke in patients with leukoaraiosis", Eur J Neurol, 17, pp.866~870 (2010)
  74. Chalela JA, "Multiple cerebral microbleeds: mri marker of a diffuse hemorrhage-prone state", J Neuroimaging, 14, pp.54~57 (2004)
  75. Fiehler J, "Bleeding risk analysis in stroke imaging before thrombolysis (brasil): pooled analysis of T2*-weighted magnetic resonance imaging data from 570 patients", Stroke, 38, pp.2738~2744 (2007)
  76. Charidimou A, "Cerebral microbleeds and the risk of intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: systematic review and meta-analysis", J Neurol Neurosurg Psychiatry, 84, pp.277~280 (2013)
  77. Dannenberg S, "Number of cerebral microbleeds and risk of intracerebral hemorrhage after intravenous thrombolysis", Stroke, 45, pp.2900~2905 (2014)
  78. Progress Management Committee, "PROGRESS-Perindopril protection Against Recurrent Stroke Study: characteristics of the study population at baseline", J Hypertens, 17, pp.1647~1655 (1999)
  79. Gueyffier F, "Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. The INDANA (INdividual dData ANalysis of Antihypertensive intervention trials) project collaborators", Stroke, 28, pp.2557~2562 (1997)
  80. Rashid P, "Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review", Stroke, 34, pp.2741~2748 (2003)
  81. Benavente OR, "Effects of clopidogrel added to aspirin in patients with recent lacunar stroke", N Engl J Med, 367, pp.817~825 (2012)
  82. Benavente OR, "Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial", Lancet, 382, pp.507~515 (2013)
  83. Dufouil C, "Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke : the PROGRESS(Perindopril pROtection aGainst REcurrent Stroke Study)magnetic resonance imaging substudy", Circulation, 112, pp.1644~1650 (2005)
  84. Muller M, "Joint effect of mid- and late-life blood pressure on the brain: the Ages-Reykjavik study", Neurology, 82, pp.2187~2195 (2014)
  85. Amarenco P, "Results of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial by stroke subtypes", Stroke, 40, pp.1405~1409 (2009)
  86. Goldstein LB, "Hemorrhagic stroke in the stroke prevention by aggressive reduction in cholesterol levels study", Neurology, 70, pp.2364~2370 (2008)
  87. Furie KL, "Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: A guideline for healthcare professionals from the American Heart Association", American Stroke Association, 2011, pp.42, 227~276
  88. Mok VC, "Effects of statins on the progression of cerebral white matter lesion: post hoc analysis of the ROCAS (Regression Of Cerebral Artery Stenosis) study", J Neurol, 256, pp.750~757 (2009)
  89. Fu JH, "Effects of statins on progression of subclinical brain infarct", Cerebrovasc Dis, 30, pp.51~56 (2010)
  90. Cavalieri M, "B vitamins and magnetic resonance imaging-detected ischemic brain lesions in patients with recent transient ischemic attack or stroke: the VITAmins TO Prevent Stroke (VITATOPS) MRI-substudy", Stroke, 43, pp.3266~3270 (2012)
  91. Gopalan Y, "Clinical investigation of the protective effects of palm vitamin E tocotrienols on brain white matter", Stroke, 45, pp.1422~1428 (2014)
  92. Bousser MG, "“AICLA” controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia", Stroke, 14, pp.5~14 (1983)
  93. Gent M, "The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke", Lancet, 1, pp.1215~1220 (1989)
  94. Gorelick PB, "Aspirin and ticlopidine for prevention of recurrent stroke in black patients : A randomized trial", JAMA, 289, pp.2947~2957 (2003)
  95. Halkes PH, "Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial", Lancet, 367, pp.1665~1673 (2006)
  96. Nonaka Y, "Cilostazol protects against hemorrhagic transformation in mice transient focal cerebral ischemia-induced brain damage", Neurosci Lett, 452, pp.156~161 (2009)
  97. Huang Y, "Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study", Lancet Neurol, 7, pp.494~499 (2008)
  98. Shinohara Y, "Cilostazol for Prevention of Secondary Stroke (CSPS2): an aspirin-controlled, double-blind, randomised non-inferiority trial", Lancet Neurol, 9, pp.959~968 (2010)
  99. Wilhite DB, "Managing pad with multiple platelet inhibitors: the effect of combination therapy on bleeding time", J Vasc Surg, 38, pp.710~713 (2003)
  100. Lee JH, "Cilostazol prevents focal cerebral ischemic injury by enhancing casein kinase 2 phosphorylation and suppression of phosphatase and tensin homolog deleted from chromosome 10 phosphorylation in rats", J Pharmacol Exp Ther, 308, pp.896~903 (2004)
  101. Kasahara Y, "Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model", Stroke, 43, pp.499~506 (2012)
  102. Uchiyama S, "Benefit of cilostazol in patients with high risk of bleeding: subanalysis of cilostazol stroke prevention study 2", Cerebrovasc Dis, 37, pp.296~303 (2014)
  103. Han SW, "Cilostazol decreases cerebral arterial pulsatility in patients with mild white matter hyperintensities: subgroup analysis from the effect of cilostazol in acute lacunar infarction based on pulsatility index of transcranial doppler (ECLIPse) study", Cerebrovasc Dis, 38, pp.197~203 (2014)
  104. Culebras A, "Triflusal vs aspirin for prevention of cerebral infarction : a randomized stroke study", Neurology, 62, pp.1073~1080 (2004)

관련 논문AI추천

Updates on Prevention of Hemorrhagic and Lacunar StrokesEric Jouvent, Hsin-Hsi Tsai, Jong S. Kim, M. Edip Gurol대한뇌졸중학회 · 대한뇌졸중영문학회지2018 · 제20권 제2호Prognostic Impact of Cerebral Small Vessel Disease on Stroke Outcome이승훈, Beom Joon Kim대한뇌졸중학회 · 대한뇌졸중영문학회지2015 · 제17권 제2호Blood Pressure Management for Stroke Prevention and in Acute Stroke홍근식대한뇌졸중학회 · 대한뇌졸중영문학회지2017 · 제19권 제2호Role of Blood Lipid Levels and Lipid-Lowering Therapy in Stroke Patients with Different Levels of Cerebral Artery Diseases: Reconsidering Recent Stroke GuidelinesJong S. Kim대한뇌졸중학회 · 대한뇌졸중영문학회지2021 · 제23권 제2호Evolving Concept of Small Vessel Disease through Advanced Brain ImagingBo Norrving대한뇌졸중학회 · 대한뇌졸중영문학회지2015 · 제17권 제2호Recent Advances in Primary and Secondary Prevention of Atherosclerotic Stroke김동억, Andrei V. Alexandrov, Apostolos Safouris, Georgios Tsivgoulis대한뇌졸중학회 · 대한뇌졸중영문학회지2018 · 제20권 제2호

이 간행물의 다른 논문 (15건)

Endovascular Therapy: A Standard Treatment?Jong S. Kimpp. 93-93Evolving Concept of Small Vessel Disease through Advanced Brain ImagingBo Norrvingpp. 94-100Prognostic Impact of Cerebral Small Vessel Disease on Stroke Outcome이승훈, Beom Joon Kimpp. 101-110Endovascular Mechanical Thrombectomy for Acute Ischemic Stroke: A New Standard of CareDale Dingpp. 123-126Evolution of Endovascular Therapy in Acute Stroke: Implications of Device DevelopmentPeter Mitchell, Adithya Balasubramaian, Richard Dowling, Bernard Yanpp. 127-137
원문 보기